Through SOX9, LRF/ZBTB7A also affects the commitment of adult mesenchymal stem cells towards undifferentiated sarcomas [92], whereas in breast cancer, LRF/ZBTB7A regulates estrogen receptor’s alpha (ERα) expression, one of the major markers used to determine course of treatment, and predicts a favorable/unfavorable outcome for patients treated with endocrine therapies [93]. Here, ZBTB7A is linked to breast carcinoma.